Malignant neoplasm of urinary bladder
|
0.400 |
Biomarker
|
disease |
BEFREE |
RASSF1A gene transfected the bladder cancer cells by lipofectamine.
|
31500788 |
2019 |
Malignant neoplasm of urinary bladder
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Three of the strong evidence associations involve RASSF1 methylation on bladder cancer risk (OR = 18.46; 95% CI: 12.69-26.85; I<sup>2</sup> = 0%), MGMT methylation on NSCLC (OR = 4.25; 95% CI: 2.83-6.38; I<sup>2</sup> = 22.4%) and RARB methylation on prostate cancer (OR = 6.87; 95% CI: 4.68-10.08; I<sup>2</sup> = 0%).
|
31202904 |
2019 |
Malignant neoplasm of urinary bladder
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Next, hmDNA levels (RASSF1A qMSP) in stored urine samples of patients suffering from bladder cancer (n = 10) or non-small cell lung cancer (NSCLC; n = 10) were measured at day 0 and 7 upon storage with and without the addition of 40mM EDTA and/or 20 μl/ml Penicillin Streptomycin (PenStrep) at RT and 4°C.
|
30142219 |
2018 |
Malignant neoplasm of urinary bladder
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
There was a significant relationship between the methylation of the RASSF1A gene promoter and bladder cancer.
|
28207521 |
2017 |
Malignant neoplasm of urinary bladder
|
0.400 |
Biomarker
|
disease |
BEFREE |
We hypothesize that this BBN-induced RGS6 loss represents a critical hit in UBC as it irrevocably impairs the anti-proliferative actions of the ATM/p53 and RASSF1A pathways.
|
27713144 |
2016 |
Malignant neoplasm of urinary bladder
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
This study showed that RASSF1A methylation appears to be an independent prognostic factor for bladder cancer.
|
23139773 |
2012 |
Malignant neoplasm of urinary bladder
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
The aim of the present study was to investigate the value of RASSF1A methylation as a prognostic marker in BC.
|
22382007 |
2012 |
Malignant neoplasm of urinary bladder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Promoter hypermethylation occurred frequently in both pathologically normal urothelium and tumor samples from bladder cancer patients, and increased with progression from normal to bladder cancer at E-cadherin (P = 0.067), p16 (P < 0.001), p14 (P = 0.01), and RASSF1A (P = 0.01).
|
20800513 |
2012 |
Malignant neoplasm of urinary bladder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Methylation-specific PCR (MSP) assay was used to detect promoter hypermethylation in 4 genes (E-cadherin, p16, p14, and RASSF1A) to identify reliable biomarkers for bladder cancer diagnosis in primary tumor DNA and urine sediment DNA from 57 bladder cancer patients.
|
19181545 |
2011 |
Malignant neoplasm of urinary bladder
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
There was no association between MTHFR gene variants and methylation status of the RASSF1A gene in the 45 bladder cancer patients in whom this was studied.
|
20146887 |
2010 |
Malignant neoplasm of urinary bladder
|
0.400 |
Biomarker
|
disease |
BEFREE |
RASSF1a/APC/p14, RAR_/DAPK/E-cadh/p16, p16/p14/MGMT/GSTP1, and RASSF1a/E-cadh/APC) are of interest in the detection of bladder cancer.
|
19522860 |
2009 |
Malignant neoplasm of urinary bladder
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
To investigate the effect of 5-Aza-CdR on methylation and expression of RASSF1A gene in the human bladder cancer BIU87 cell line.
|
19172108 |
2009 |
Malignant neoplasm of urinary bladder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although no statistically significant differences were found between RARB and RASSF1A methylation and the clinical and histopathological parameters in bladder cancer, a sensitivity of 95% and a specificity of 71% were observed for RARB methylation (Fisher's Exact test (p < 0.0001; OR = 48.89) and, 58% and 17% (p < 0.05; OR = 0.29) for RASSF1A gene, respectively, in relation to the control group.
|
18702824 |
2008 |
Malignant neoplasm of urinary bladder
|
0.400 |
Biomarker
|
disease |
BEFREE |
We, therefore, examined, in a population-based study of human bladder cancer (n = 351), the relationship between epigenetic silencing of the tumor-suppressor genes, p16(INK4A), RASSF1A, PRSS3, and the four SFRP genes and exposure to both tobacco and arsenic in bladder cancer.
|
17119258 |
2006 |
Malignant neoplasm of urinary bladder
|
0.400 |
Biomarker
|
disease |
BEFREE |
A quantitative fluorogenic real-time polymerase chain reaction (PCR) assay was used to examine primary tumor DNA and urine sediment DNA from 15 patients with bladder cancer and 25 control subjects for promoter hypermethylation of nine genes (APC, ARF, CDH1, GSTP1, MGMT, CDKN2A, RARbeta2, RASSF1A, and TIMP3) to identify potential biomarkers for bladder cancer.
|
16849682 |
2006 |
Malignant neoplasm of urinary bladder
|
0.400 |
Biomarker
|
disease |
CTD_human |
Promoter methylation of each of these genes occurred in approximately 30% of bladder cancers, and both RASSF1A and PRSS3 promoter methylation were associated with advanced tumor stage (P<0.001 and P<0.04, respectively).
|
15987713 |
2006 |
Malignant neoplasm of urinary bladder
|
0.400 |
Biomarker
|
disease |
BEFREE |
We, therefore, examined, in a population-based study of human bladder cancer, the relationship between epigenetic silencing of three tumor suppressor genes, p16(INK4A), RASSF1A and PRSS3, and exposure to both tobacco and arsenic in bladder cancer.
|
15987713 |
2006 |
Malignant neoplasm of urinary bladder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We aimed to investigate the methylation status of RASSF1A and the frequency of LOH in 3p21.3 region in bladder cancer.
|
12594816 |
2003 |